https://www.live-feeds.com/feed/ultragenyx-reports-third-quarter-2026-financial-results-announces-substantial-expense-reductions-and-reaffirms-profitabiContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/ultragenyx-reports-third-quarter-2026-financial-results-announces-substantial-expense-reductions-and-reaffirms-profitabihttps://www.live-feeds.com/feed/ultragenyx-reports-third-quarter-2026-financial-results-announces-substantial-expense-reductions-and-reaffirms-profitabi#u188368Mon, 09 Nov 2026 16:36:25 +0000Ultragenyx Pharmaceutical reported third-quarter 2026 total revenue of $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. Alongside its financial results, the company announced major structural changes, including a 20% workforce reduction and the elimination of assets like a Wilson disease gene therapy to slash research and development spending. Management reaffirmed its financial targets, aiming for profitability in 2027 and maintaining full-year 2026 revenue guidance between $730 million and $760 million. The restructuring is expected to cut 2027 research and de